Hebei Changshan Biochemical Pharmaceutical Co Ltd. Stock Analysis 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, sale of heparin series products and preparations. The company is headquartered in Shijiazhuang, Hebei and currently employs 1,194 full-time employees. The company went IPO on 2011-08-19. The products primarily include crude heparin sodium, heparin sodium API, heparin sodium injection, low molecular weight heparin calcium API and low molecular weight heparin calcium injection, enoxaparin sodium API and enoxaparin sodium injection, nadroparin calcium API and nadroparin calcium injection, as well as dalteparin sodium API and dalteparin sodium injection. The firm is also engaged in the development of the glucagon-like peptide-1 receptor agonist (GLP-1RA) ibenatide, as well as the research, development and crude product procurement of low molecular weight heparins from non-porcine sources such as bovine and ovine sources. The firm primarily operates its businesses in the domestic market and overseas markets.